







CHALLENGING ASSUMPTIONS in PERITONEAL DIALYSIS





All sessions will have at least 25% of the time available for discussion.

THURSDAY APRIL 9[™], 2015

All sessions take place in the Harbourside Ballrooms I & II unless otherwise noted.

TIME	SESSION	LEARNING OBJECTIVES
7:45 – 8:45 AM	Continental Breakfast - 2 nd Floor Harbourside Foyer	
8:50 – 9:00 AM	Welcome and Opening Remarks - Dr. Paul Taylor	
9:00 – 10:30 AM Chair: Dr. Paul Taylor	9:00 - 9:45 AM Use of PD in AKI: A Reawakening Keynote Speaker: Dr. Fred Finkelstein 9:45 - 10:15 AM Urgent Starts PD Speaker: Dr. Daniel Schwartz 10:15 - 10:30 AM - Questions for Pane	 To review and understand the guidelines for the use of PD to treat patients with AKI. To review and understand the use of PD for AKI, from a global perspective. To understand the rationale for urgent starts in PD. To review barriers & solutions to achieving urgent starts in PD.
10:30 – 11:00 AM	Networking Break	
11:00 – 12:15 PM Chair: Janice James	 11:00 - 11:30 AM The ISPD North American Research Consortium Speaker: Dr. Robert Quinn 11:30 AM - 12:00 PM Standardizing PD Education Speaker: Dr. Braden Manns 12:00 - 12:15 PM - Questions for Pane 	 To review history and progress to date of the ISPD North American Research Consortium. To discuss research and quality improvement plans for the North American Research Consortium. To determine strategies proven to increase PD use. To describe the elements of effective PD.
12:15 – 1:15 PM	Lunch and Networking Break	
1:15 – 1:30 PM	Honouring Dr. Karl Nolph - Dr. Mrinal Dasgupta	
1:30 – 3:00 PM Chair: Laurie Herman	1:30 - 2:30 PM Managing Diabetes with PD: Teamwork Speakers: Pat Holmes & Sharon Kelly 2:30 - 3:00 PM Medication Management in PD Patients Speaker: Dr. Clifford Lo & Claudia Ho	 To identify & understand factors that influence glycemic control in diabetes and PD. To understand & evaluate pharmacologic & lifestyle strategies to manage diabetes with PD. To discuss pharmacokinetic principals in relation to PD patients. To review dosing strategies for commonly prescribed medications in PD patients.
3:00 – 3:30 PM	Networking Break	
3:30 – 5:00 PM	Provincial Updates: Greatest Successes and Challenges Chair: Dr. Paul Taylor Updates from BC, Alberta, Saskatchewan and Manitoba.	
5:00 PM	Closing Remarks - Dr. Paul Taylor	
5:00 – 6:00 PM	Walk the Stanley Park Seawall	
6:15 PM	Networking Dinner : Pinnacle Hotel Vancouver Harbourfront - Vista's Revolving Restaurant, 19 th floor Doors open at 6:15 PM. Please note this is a cash bar.	

FRIDAY APRIL 10TH, 2015

All sessions take place in the Harbourside Ballrooms I & II unless otherwise noted.

TIME	SESSION	LEARNING OBJECTIVES
7:45 – 8:45 AM	Continental Breakfast	
8:50 – 9:00 AM	Opening Remarks and Announcement Dr. Paul Taylor	5
9:00 – 10:45 AM Chair: Dr. Mrinal Dasgupta	9:00 - 10:00 AM Outreach, Locally and Internationally Speaker: To Be Announced	Learning objectives to be announced.
	10:00 - 10:45 AM International Perspective on PD	 To understand the current practice of PD from a global perspective.
	Keynote Speaker: Dr. Fred Finkelstein	 To understand the different practice patterns of PD globally.
10:45 – 11:15 AM	Networking Break	
11:15 – 12:15 PM Chair: Dr. Abeed Jamal	 11:15 - 11:45 AM DMAR Calgary: Two Years of Quality Improvement Speaker: Dr. Robert Quinn 11:45 AM - 12:05 PM Patient Profile Project in BC Speaker: Sarah Carriere 12:05 - 12:15 PM - Questions for Pane 	 To review and understand the importance of the collection of data for quality improvement. To give a real-life example of how data is used to inform decision making. To be able to see the person before the patient. To understand the importance of a venue for patients to create a snapshot of their own personhood.
12:15 – 1:15 PM	Lunch and Networking Break	
1:15 – 2:30 PM	Breakout Sessions	
	Adaptive APD Chair: Dr. Colin White Speaker: Dr. Michel Fischbach	 To understand the importance of varying dwell times and dwell volumes to optimize dialysis prescriptions. To understand the importance of optimizing volume control.
	Social Workers - Level A, Salon E Co-chairs: Neil Thompson, AB and Neelam Mann, BC	
	Dietitians - 2nd Floor, Port of Vancouve Chair: Marianna Fiocco, BC	r
2:30 PM	Closing Remarks Dr. Paul Taylor	



CSN/SCN

Canadian Society of Nephrology/ Société canadienne de néphrologie This activity is an Acc

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Nephrology.



Committee Members

Stephanie Allan Ashley Bhadrasen Katie Cave Jennifer Chow Mrinal Dasgupta Henni Dyck Karen Forsberg Laurie Hermann Abeed Jamal Janice James Teresa Ma George Pylypchuk* (Co-Chair) Sushila Saunders Daniel Schwartz Paul Taylor* (Co-Chair) Mary Van Der Hoek Mauro Verrelli Berlene Villanueva Colin White Teri Wiwchar

Speaker Bios



Braden Manns, MD, MSc, FRCPC, is a professor and nephrologist at the University of Calgary in the Departments of Medicine and Community Health Sciences, as well as an Alberta Innovates – Health Solutions Health Scholar. He has expertise in applied health economics and clinical research in nephrology, and is co-PI for an inter-disciplinary team grant investigating chronic kidney disease (www.icdc.ca). He is the scientific director of the Alberta Health Services Kidney – Strategic Clinical Network, and also holds the Svare Chair in Health Economics at the University of Calgary. Dr. Manns' current research interests include examining the cost effectiveness of strategies and health care policies for managing patients with chronic kidney disease. Dr. Manns is also the president of the Canadian Society of Nephrology and principle investigator of a Canadian kidney disease knowledge translation network, guiding health policy for patients with kidney disease (www.CANN-NET.ca)

Claudia Ho, Bsc Pharm, ACPR, is currently a clinical pharmacist on the general medicine unit at Surrey Memorial Hospital, in Surrey, BC. She has been working closely with PD and HD patients since the unit's inception in June 2014.

Clifford Lo, BSc, MHA, PharmD, BCPS, currently splits his time between Fraser Health where he is a renal pharmacist, and the BC Provincial Renal Agency where he is an administrative fellow. His professional interests include patient safety and quality in addition to research and theory in the efficient allocation of resources.

Daniel Schwartz, **MD**, **FRCPC**, is the medical director of the Fraser Health renal program and program lead for the Fraser Health peritoneal dialysis program. He received his training at the University of British Columbia and the University of Toronto. Clinically, his primary interests are peritoneal dialysis and interventional nephrology, and he is also focused on knowledge translation at the point of care, and the intersection of information technology with clinical medicine.

Fredric Finkelstein, **MD**, is a clinical professor of medicine at Yale University and has been engaged in PD related research for over four decades. He holds numerous chair positions, including: chair of the ISN Continuing Medical Education Program, co-chair of the ISN Dialysis Committee and chair of the International Liaison Committee of the ISPD. Additionally, he was co-principal investigator of the recently published guidelines for the use of PD to treat patients with AKI.

Michel Fischbach, MD, is a professor of pediatrics and is head of the Pediatric Nephrology Department at the University Hospital of Strasbourg in France. He is coordinator for the Center of Competence: maladies rénales and junveniles arthritis, and is focused on dialysis transplantation and dialysis prescription in children. Additionally, he is a member of the INSERM Unit 727 and the INSERM Unit 682 at the Strasbourg University Medical School and sits on the management board for the European Training & Research in Peritoneal Dialysis (Marie Curie). He has numerous publications with a primary focus on peritoneal dialysis.

Pat Holmes, Bsc, MSc, BN, is a diabetic nurse clinician at the South Alberta Renal Program for the chronic kidney disease, peritoneal dialysis and hemodialysis programs. She has previous diabetes experience in the community and transplant clinic as well as in cardiology, ICU and thoracic surgery. Prior to becoming a nurse, she obtained an MSc in exercise physiology and worked for 15 years in cardiac rehab. She also obtained a BSc at Acadia University, an MSc at the University of Alberta and a BN from the University of Calgary.

Robert Quinn, MD, PhD, FRCPC, is a nephrologist and assistant professor at the University of Calgary. His primary research is focused on vascular access, peritoneal dialysis and quality improvement.

Sarah Carriere, RN, has a background in critical care nursing. She previously worked as a change specialist for St. Paul's Hospital and currently spends her time working both at the beside and as a project leader for QI initiatives taken from ideas generated at the front line and nurse led research studies.

Sharon Kelly, BN, has worked in diabetes in renal disease, hemodialysis and PD since 2008. After receiving a Bachelor of Nursing at the University of Calgary in 1988, she went on to work at the Diabetes Centre at Foothills Medical Centre in 1990. From 1997-2008, she worked with diabetes patients with kidney disease and transplants.





PLATINUM SPONSOR

As the Canadian subsidiary of Baxter International Inc., **Baxter Corporation** manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. <u>www.baxter.ca</u>

GOLD SPONSORS

AMGEN[®]

Amgen Canada Inc., discovers, develops and delivers innovative human therapeutics. Our medicines have helped millions of patients in the fight against kidney disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, we continue to advance science to serve patients. <u>www.amgen.ca</u>



Takeda has always been driven by passion: the passion to build a healthier society. Takeda is dedicated to pharmaceutical innovation, tackling diseases for which there is currently no cure and expanding into new fields of treatment and therapy. Our commitment is to improve the quality of the most precious thing we know: life. <u>www.takedacanada.com</u>

SILVER SPONSORS

Covidien and Medtronic are committed to improving the lives of patients through ground-breaking medical technologies. By bringing our companies together, we are able to expedite our ability to create the meaningful innovations and therapies that fuel our mission to improve patients' lives. This partnership will create new opportunities for skilled, ambitious people to change the way we work, and ultimately deliver better health for more people. Learn more at <u>www.covidien.com</u>

Fresenius Medical Care, the world's largest fully integrated renal healthcare company, conducts business in three areas: dialysis and renal services, dialysis products and home care. Fresenius' clear focus is to provide quality products and services to patients with renal disease through leadership in product innovations for hemodialysis and peritoneal dialysis. Learn more at <u>www.fmcna.com</u>

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents ground-breaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at <u>www.genzyme.com</u>

Sanofi, the manufacturer of Renagel and Ferrlecit is a global and diversified healthcare leader. Sanofi has core strengths in the field of healthcare with many platforms including diabetes solutions, human vaccines, consumer healthcare, and Renal. Learn more at <u>www.sanofi.ca</u>

Janssen Inc., is dedicated to addressing and solving important unmet medical needs. Driven by our commitment and passionate pursuit of science for the benefit of patients, we work together with healthcare providers to bring innovative medicines and services to patients to improve, extend and save lives every day. Learn more at <u>www.janssen.ca</u>

PD Education Materials are Available from the BC Renal Agency!



These videos can also be viewed online on our Tube YouTube channel: youTube channel: youTube channel: youTube channel: youTube channel:

DVDs


- Flexibility and Freedom on Peritoneal Dialysis A video that highlights the advantages of peritoneal dialysis. English, Mandarin, Cantonese, Punjabi and Tagalog versions on one DVD.
- Peritoneal Dialysis Training Video: A Step-by-Step Guide to Maintaining Your Independence Designed to help support patients who are training for peritoneal dialysis, this DVD takes viewers stepby-step through both types of peritoneal dialysis -- Continuous Ambulatory Peritoneal Dialysis (CAPD), and Automated Peritoneal Dialysis (APD). English, Mandarin, Cantonese, Punjabi and Tagalog versions on one DVD.



Handouts

You

- **Dialysis Options in BC** Includes comprehensive information about independent dialysis options for patients in BC, including benefits, drawbacks, training, support, and costs.
- **Diet for Peritoneal Dialvsis** Download the PDF here: bcrenalagency.ca/node/1223



Coming Soon!


The BC Renal Agency is developing a series of e-learning modules for patients preparing for peritoneal dialysis (PD). The series of seven computer-based modules explains all of the steps involved in both continuous ambulatory PD (CAPD) and automated PD (APD) and provides guidance for how to live well on PD.

The modules are designed to allow self-paced learning and will be available both online and as portable digital files stored on DVDs and USB drives. The PD e-learning series is expected to be ready for use by patients with their PD educators by the summer of 2015.





Order online at bcrenalagency.ca/print-video-order-form



Visit our website: wcppdays.ca